Meeting
2020 ASCO Virtual Scientific Program
ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).
Authors
Ji-Youn Han
Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South Korea
Ji-Youn Han , Myung-Ju Ahn , Sang-We Kim , Ki Hyeong Lee , Eun Kyung Cho , Yun-Gyoo Lee , Dong-Wan Kim , Joo-Hang Kim , Jong-Seok Lee , Gyeong-Won Lee , Byoung Yong Shim , Jin-Soo Kim , Sang Hoon Chun , Sung Sook Lee , Young Joo Min , Sang Won Shin , Arielle Yablonovitch , Carin R. Espenschied , Hyunwoo Jang , Byoung Chul Cho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03046992
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9601)
DOI
10.1200/JCO.2020.38.15_suppl.9601
Abstract #
9601
Poster Bd #
367
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Next generation sequencing (NGS) based mutation profiling and heterogeneity of resistance mechanisms to AZD9291.
First Author: Jun Zhao
Poster
2017 ASCO Annual Meeting
Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.
First Author: Nicolas Marie Guibert
Poster
2023 ASCO Annual Meeting
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
First Author: Alissa Jamie Cooper
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates